Olema Pharmaceuticals (OLMA) Free Cash Flow (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Free Cash Flow data on file, last reported at -$46.0 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 4.57% year-over-year to -$46.0 million in Q1 2026; TTM through Mar 2026 was -$148.7 million, a 19.13% decrease from a year earlier, with the FY2025 full-year figure at -$146.7 million, down 40.38% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$46.0 million, down from -$38.3 million in the prior quarter.
• Over the last five years, Free Cash Flow for OLMA reached as high as -$17.9 million in Q1 2022 and fell as low as -$46.0 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$27.3 million across 5 years, with a median of -$26.3 million in 2024.
• Across the five-year window, Free Cash Flow plunged 196.56% in 2022 and rose 16.48% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$19.9 million in 2022, then increased by 7.08% to -$18.5 million in 2023, then tumbled by 42.26% to -$26.3 million in 2024, then slumped by 45.82% to -$38.3 million in 2025, then dropped by 19.99% to -$46.0 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$46.0 million in Q1 2026, -$38.3 million in Q4 2025, and -$34.5 million in Q3 2025.